1.08

0.92% -0.01

Biocardia Inc (BCDA)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Biocardia Inc stock is traded at $1.08, with a volume of 57,234. It is down -0.92% in the last 24 hours and up +18.66% over the past month. BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Previous Close:

$1.09

Open:

$1.07

24h Volume:

57,234

Relative Volume:

0.02

Market Cap:

$16.35M

Revenue:

$3,000

Net Income/Loss:

$-7.78M

P/E Ratio:

-1.0439

EPS:

-1.0346

Net Cash Flow:

$-7.49M

1W Performance:

-6.09%

1M Performance:

+18.66%

6M Performance:

-9.24%

1Y Performance:

-47.06%

1-Day Range:

$1.06

$1.085

1-Week Range:

$1.06

$1.17

52-Week Range:

$0.75

$2.29

Biocardia Inc Stock (BCDA) Company Profile

Name

Biocardia Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

650-226-0123

Address

320 SOQUEL WAY, SUNNYVALE, CA

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

BCDA's Discussions on Twitter

Compare BCDA vs PSNYW, GOODO, SHMD, DWLD, QQQE

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BCDA	0.41	0	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	5.00	394.14M	2.07B	-1.42B	-1.37B	-0.6765
GOODO Gladstone Commercial Corporation	20.92	372.90M	0	0	0	0.00
SHMD Schmid Group N V	3.15	315.90M	52.15M	-21.46M	0	-0.4675
DWLD Davis Select Worldwide ETF	47.39	0	0	0	0	0.00
QQQE Direxion NASDAQ-100 Equal Weigh	120.75	0	0	0	0	0.00

Biocardia Inc Stock (BCDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

Biocardia Inc Stock (BCDA) Latest News

Aug 21, 2026

BioCardia Received Notice of Noncompliance - TradingView

Aug 21, 2026

Aug 20, 2026

BioCardia’s Q2 2026 Update Keeps the Regulatory Story Alive, but Capital Still Drives the Risk - AlphaStreet

Aug 20, 2026

BCDA Q2 2026 Earnings: EPS Surprise of 29.19% Narrows Losses as Shares Climb 4.82%Estimate Revision Count - vinanet.vn

Aug 17, 2026

BioCardia (BCDA) CEO buys 5,400 shares in open market - Stock Titan

Aug 17, 2026

Aug 15, 2026

BioCardia (BCDA) Pushes Higher: Micro-Cap Biotech Gains 4.8% as It Nears $1.02 ResistanceIceberg Order - vinanet.vn

Aug 15, 2026

BCDA Q2 2026 Earnings: Narrower-than-Expected Loss Drives Shares Up 4.82%Earnings Revision Upgrade - vinanet.vn

Aug 15, 2026

Aug 13, 2026

BioCardia CEO Peter Altman buys $1,748 in company stock By Investing.com - Investing.com Canada

Aug 13, 2026

BioCardia CEO Peter Altman buys $1,748 in company stock - Investing.com

Aug 13, 2026

BioCardia (BCDA) CEO Peter Altman purchases 1,900 shares at $0.92 average price - Stock Titan

Aug 13, 2026

BioCardia (BCDA) Holds at $0.88 as Range-Bound Trading PersistsTriple Top - vinanet.vn

Aug 13, 2026

BioCardia (BCDA) Drops 5.6% to $0.88 as Micro-Cap Biotech Tests Support LevelInsider Buying Alerts - vinanet.vn

Aug 13, 2026

BioCardia (BCDA) Advances Regulatory Pathway, Faces High Price-t - GuruFocus

Aug 13, 2026